Cambridge biotech firm Moderna wins Zika vaccine grant : bostonglobe

as declared in bostonglobe

Cambridge biotech firm Moderna wins Zika vaccine grant

Cambridge biotech firm Moderna wins Zika vaccine grant

Cambridge biotech firm Moderna Therapeutics Inc. has won an $8 million federal grant to accelerate its development of a vaccine for the Zika virus.The award from the Biomedical Advanced Research and Development Authority, or BARDA, part of the US Department of Health and Human Services, will help fund initial human studies of a potential vaccine for the virus, according to a press release from the firm.AdvertisementIf early trials succeed, the grant could swell to $125 million to support final testing and large-scale manufacturing — assuming Congress passes a bill to fund a coordinated US fight against Zika, for which there is currently no treatment.


coupled with homelandprepnews

HHS awards $19.8 million for development of Zika virus vaccine

HHS awards $19.8 million for development of Zika virus vaccine

Richard HatchettThe U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) recently provided Takeda Vaccines, Inc., with a grant to develop a Zika virus vaccine.The grant, worth $19.8 million, will be spaced out over the course of the next 18 months.ASPR's Biomedical Advanced Research and Development Authority (BARDA) will provide the funding to complete studies that should allow Takeda to file an investigational new drug application with the U.S. Food and Drug Administration (FDA).


in addition healthcarefinancenews

HHS gives $8 million to Moderna Therapeutics to speed development of Zika vaccine

HHS gives $8 million to Moderna Therapeutics to speed development of Zika vaccine

Just one day after Congress failed for the third time to pass Zika funding legislation, HHS Office of the Assistant Secretary for Preparedness and Response has announced an $8.2 million contract awarded to Moderna Therapeutics to accelerate the development of a vaccine.The initial four-year agreement with ASPR's Biomedical Advanced Research and Development Authority and the Cambridge, Massachusetts based Moderna will support a Phase 1 clinical trial, toxicology studies, vaccine formulation, and manufacturing, HHS said in a statement.[Also: Doctors, experts stress need for extended monitoring of Zika-exposed infants]The agreement could be extended an additional year to five years and a total of $125.5 million in support of Phase 2 and 3 clinical trials, as well as large scale manufacturing.


let alone fiercepharma

Takeda advances dengue vaccine into Phase III on heels of Zika R&D plunge

Takeda advances dengue vaccine into Phase III on heels of Zika R&D plunge

Taking the next step toward challenging Sanofi's first-to-market Dengvaxia, on Wednesday, Takeda kicked off a global Phase III trial of its dengue vaccine, TAK-003.The announcement comes just days after the company pushed into another mosquito-borne disease, Zika, through a $312 million R&D deal with the U.S. government.Takeda vaccinated the first subject in a dengue study that'll include more than 20,000 participants aged 4 to 16 in endemic nations in Latin America and Asia.